The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Dolsten Mikael since 2013.
This trader's CIK number is 1437590.
At the time of last reporting, Dolsten Mikael was the President R&D of Pfizer Inc. (stock ticker symbol PFE).
Also see all insider trading activities at Pfizer Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2022 | PFE | 0 | $0 | 63,902 | $3,152,605 | 102,460 | $3,383,741 |
| 2021 | PFE | 0 | $0 | 59,664 | $3,001,636 | 270,735 | $7,191,685 |
| 2020 | PFE | 0 | $0 | 95,353 | $3,602,913 | 0 | $0 |
| 2019 | PFE | 0 | $0 | 149,553 | $6,515,053 | 232,159 | $7,237,947 |
| 2018 | PFE | 0 | $0 | 148,272 | $5,443,612 | 554,031 | $13,554,894 |
| 2017 | PFE | 0 | $0 | 89,816 | $3,084,986 | 218,447 | $4,593,940 |
| 2016 | PFE | 0 | $0 | 0 | $0 | 210,280 | $3,974,291 |
| 2015 | PFE | 0 | $0 | 58,298 | $2,008,074 | 146,396 | $2,589,745 |
| 2014 | PFE | 0 | $0 | 35,789 | $1,165,826 | 0 | $0 |
| 2013 | PFE | 0 | $0 | 30,582 | $859,812 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-05-11 | PFE | Sale | 63,902 | 49.34 | 3,152,605 |
| 2022-03-03 | PFE | Option Ex | 102,460 | 33.02 | 3,383,741 |
| 2021-12-17 | PFE | Option Ex | 71,187 | 30.17 | 2,147,711 |
| 2021-11-11 | PFE | Option Ex | 199,548 | 25.28 | 5,043,974 |
| 2021-11-11 | PFE | Sale | 59,664 | 50.31 | 3,001,636 |
| 2020-05-18 | PFE | Sale | 95,353 | 37.78 | 3,602,913 |
| 2019-03-01 | PFE | Option Ex | 106,191 | 31.41 | 3,335,459 |
| 2019-03-04 | PFE | Sale | 49,082 | 43.54 | 2,137,030 |
| 2019-03-01 | PFE | Sale | 100,471 | 43.58 | 4,378,023 |
| 2019-01-31 | PFE | Option Ex | 125,968 | 30.98 | 3,902,488 |
| 2018-09-13 | PFE | Option Ex | 181,712 | 26.63 | 4,838,990 |
| 2018-03-09 | PFE | Sale | 69,699 | 36.58 | 2,549,589 |
| 2018-03-02 | PFE | Sale | 13,986 | 35.85 | 501,398 |
| 2018-02-28 | PFE | Option Ex | 198,238 | 27.37 | 5,425,774 |
| 2018-02-27 | PFE | Sale | 64,587 | 37.05 | 2,392,625 |
| 2018-02-24 | PFE | Option Ex | 174,081 | 18.90 | 3,290,130 |
| 2017-03-01 | PFE | Sale | 15,569 | 34.48 | 536,819 |
| 2017-03-02 | PFE | Sale | 15,401 | 34.55 | 532,104 |
| 2017-02-27 | PFE | Sale | 58,846 | 34.26 | 2,016,063 |
| 2017-02-23 | PFE | Option Ex | 218,447 | 21.03 | 4,593,940 |
| 2016-02-24 | PFE | Option Ex | 210,280 | 18.90 | 3,974,291 |
| 2015-03-05 | PFE | Sale | 58,298 | 34.45 | 2,008,074 |
| 2015-02-25 | PFE | Option Ex | 146,396 | 17.69 | 2,589,745 |
| 2014-03-04 | PFE | Sale | 35,789 | 32.58 | 1,165,826 |
| 2013-03-06 | PFE | Sale | 30,582 | 28.11 | 859,812 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Dolsten Mikael (President R&D of Pfizer Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.